In a preliminary analysis of ongoing Phase II trials of Biomira's Theratope therapeutic vaccine in patients with advanced breast, ovarian and colorectal cancer, 48%, or 42 or the 87 evaluable patients, showed non-progressive disease, while suffering none of the toxic side effects associated with chemotherapy and radiation therapy, reported Mark Reddish, director of immunology at Biomira, at the eighth Annual Stuttgart Symposium on Immunotherapy in Germany.
No median survival rate data was available as the results were only preliminary. However, 82% of the breast cancer patients, 68% of the ovarian cancer patients and 52% of the colorectal cancer patients remain alive.
Also reporting at the meeting, Jay Gold, from the Mount Sinai Hospital in New York, said that in a physician-sponsored trial, tumor shrinkage was observed in patients with chemotherapy-resistant breast and gastrointestinal cancers using a combination protocol of Theratope and other biomodulators, including alpha-interferon and low-dose mitomycin-C. Of the 28 evaluable patients, said Dr Gold, 73% of the GI and 71% of the breast cancer patients have shown nonprogressive disease. In addition, he said, a combination of complete, partial and minor tumor response was observed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze